Interview: June Raine and the rise of pharmacovigilance and risk management
This article was originally published in SRA
Barely three years old, the Pharmacovigilance Risk Assessment Committee is the European Medicine Agency's new kid on the block. The PRAC, according to its chair Dr June Raine, is a "clear voice for public health" that will only get louder as companies and regulators increasingly focus on providing earlier access to medicines and demand for real life data grows. Dr Raine talks to Scrip Regulatory Affairs about the PRAC's role in risk management, adaptive pathways, data gathering and the voice of the patient.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.